Tau PET in Imaging and Cognition: Healthy Adults From 55-90
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: 18F-MK-6240.
- Who it may be relevant to
- Registry conditions: Mild Cognitive Impairment, Aging. Basic parameters: 55 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Tau Positron Emission Tomography (PET) in Imaging and Cognition
Overview
The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.
Detailed description
Many cognitively healthy older adults have, upon post mortem evaluations, been found to have varying amounts of neurofibrillary tangles (tau) and beta-amyloid plaque deposits, which are the hallmark brain pathologies known to be associated with Alzheimer's disease and various other dementias. While some with these pathologies may not clinically express cognitive decline or dementia in their lifetime, human post-mortem studies suggest that increasing neurofibrillary tangle density correlates with neurodegeneration and cognitive impairment.
Imaging tauopathy in-vivo provides an opportunity to examine neurocognitive correlates of differential levels of tauopathy in the brain, allowing to further qualify pre-clinical states of cognitive impairment. The investigators aim to investigate possible protective mechanisms, such as cognitive reserve, that may modulate the relationship between tauopathy and cognitive decline.
Interventions
- Drug 18F-MK-6240
Results of the 18F-MK-6240 PET scan will be correlated with other observations.
Primary outcome measures
- Total number of individuals with tau present [Time frame: Up to 5 years]
- Cognition [Time frame: Up to 5 years]
- Functional imaging (fMRI) [Time frame: Up to 5 years]
Eligibility criteria
Inclusion criteria
- Aged 55-90
- Previously received an amyloid PET scan
- Residing near Columbia University Medical Center
- Must be willing and able to participate
Exclusion criteria
- Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour)
- Pregnancy
- Lactating Women
- Current, past, or anticipated exposure to radiation
- Significant active physical illness
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Columbia University Medical Center — New York
Identifiers
NCT: NCT03372317 · AAAR6959 · 2RF1AG038465-06